Sunshine Biopharma Inc. — Form 8-K Summary
Filing/event dates: The report covers a registered public offering priced October 8, 2026, and closed October 9, 2026. This is a financing event, not a periodic financial report.
Offering and financial impact
- The company reported approximately $6 million in gross proceeds, before placement-agent fees and other expenses. Net proceeds are not stated.
- The offering comprised 10,509,082 common units at $0.55 each and 400,000 pre-funded units at $0.54999 each. Each common unit included one common share and two Series D warrants; each pre-funded unit included a pre-funded warrant for one share and two Series D warrants. The pre-funded warrants were exercised in full before closing.
- The placement agent received a fee of 7% of the public offering price, a non-accountable expense allowance of 1%, and reimbursement of certain accountable expenses.
- No revenue, profit, cash-flow, margin, debt, liquidity, or operating-performance figures are provided in this filing.
Material changes, terms, and risks
- The filing does not provide a prior-period comparison or management guidance. It does not describe planned uses of proceeds.
- Series D warrants are immediately exercisable at $0.66 per share and expire five years after issuance. They include a potential one-time adjustment following a qualifying share-combination event: the exercise price may be reduced, subject to a $0.275 floor, with a corresponding increase in shares issuable. The adjustment is subject to required Nasdaq stockholder approval.
- The offering adds common shares and warrants that may create dilution if exercised. The filing does not quantify the resulting ownership dilution.
Important facts for investors to verify
- Net proceeds after placement-agent compensation and all offering expenses, and the company’s intended use of the funds.
- Final issued share count, warrant coverage, and potential dilution, including the effect of warrant exercises or any adjustment provisions.
- The complete placement agent agreement and warrant terms filed as exhibits, along with the final prospectus.